U.S. markets closed

Incannex Healthcare Limited (IHL.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.3100-0.0200 (-6.06%)
At close: 04:10PM AEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3300
Bid0.3050 x 19574500
Ask0.3100 x 30420000
Day's Range0.3050 - 0.3250
52 Week Range0.1850 - 0.7550
Avg. Volume3,813,271
Market Cap397.522M
Beta (5Y Monthly)2.47
PE Ratio (TTM)N/A
EPS (TTM)-0.0120
Earnings DateAug 29, 2022 - Sep 02, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for IHL.AX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Incannex Appoints FDA Regulatory Affairs Expert Mr Robert B. Clark to the Board of Directors

      Highlights: Highly experienced pharmaceutical executive with 20+ years at Pfizer and 10+ years at Novo NordiskSecured FDA registration and marketing approval for 12 significant new drugs in the past 10 years at Novo Nordisk in his capacity of Vice President – US Regulatory AffairsPersonal leadership of more than 15 successful US FDA Advisory Committee Meetings on behalf of Novo Nordisk and PfizerNationally recognized expert on FDA/EMA liaison interactions and US pharmaceutical advertising and pr

    • Simply Wall St.

      Do Institutions Own Incannex Healthcare Limited (ASX:IHL) Shares?

      The big shareholder groups in Incannex Healthcare Limited ( ASX:IHL ) have power over the company. Large companies...

    • PR Newswire

      Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

      Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has engaged Curia Global, Inc. ('Curia') to further develop and manufacture GMP-grade IHL-216A, Incannex's proprietary inhaled drug product for the treatment of concussion and traumatic brain injury ('TBI').